At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 28 enrolled
Drug / intervention
RZL-012 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single Blind, Randomized, Placebo-controlled, Phase 2a, 2-cohort Study for the Evaluation of Safety and Efficacy of RZL-012 for Submental Fat Reduction in Healthy Volunteers.
In Brief
A Phase 2 clinical trial evaluating RZL-012 and Placebo for Submental Fat. Completed, enrolled 28 participants across 1 site.
Detailed Summary
Twenty-Eight (28) subjects (12 for cohort 1 and 16 for cohort 2 ) will be included in the study. Subjects in each cohort will be injected with a different dose of RZL-012. The total of 28 subjects will be enrolled in 2 clinical sites.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSubmental Fat
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedSep 2019
Enrollment StartFeb 2020
Primary CompletionSep 2020
TodayJul 2026
First PostedSep 12, 2019
Enrollment StartFeb 25, 2020
Primary CompletionSep 16, 2020
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 6.8 years ago
Interventions
RZL-012drug
Subcutaneous injection to the submental fat area
Placebodrug
Placebo